Livalo Lawsuit: Does Use of “PITAVA” by Generic Makers Infringe Kowa Trademark?
To read the full story
BUSINESS
- RaQualia’s Acid Reducer Now Available in 5 Latin American Countries
December 13, 2024
- Daiichi Kicks Off PIII Quizartinib Study for FLT3-ITD Negative AML
December 12, 2024
- Kyowa Kirin to Globalize Research Organization after Orchard Buy
December 12, 2024
- Santen’s Glaucoma Drug Accepted for Review in Korea, Vietnam
December 12, 2024
- Eisai’s Gout Drug Urece Wins Nod in China
December 12, 2024
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…